Passage BIO PASG 深 沪
已收盘 04-02 16:00:00 美东时间
8.08
+0.230
+2.93%
华盛通- 最 高8.175
- 今 开7.68
- 成交量 1.83万股
- 最 低 7.50
- 昨 收 7.85
- 总市值 2591.91万
- 52周最高 20.00
- 市盈率 静 --
- 换手率 0.57%
- 52周最低 5.1239
- 委 比 58.73%
- 总股本 320.78万
- 历史最高 764.60
- 量 比 0.56
- 振 幅 8.60%
- 历史最低 5.14
- 每 手 1
- 风险率 2.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
Oppenheimer Initiates Coverage On Passage Bio with Outperform Rating, Announces Price Target of $30
Oppenheimer analyst Jay Olson initiates coverage on Passage Bio (NASDAQ:PASG) with a Outperform rating and announces Price Target of $30.
03-31 21:58
Passage Bio Ends Hopewell Lab Lease, Extends Cash Runway
Passage Bio ( ($PASG) ) has issued an announcement. On March 4, 2026, Passage B...
03-10 19:55
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价
今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元
03-05 13:56
Canaccord Genuity Maintains Buy on Passage Bio, Lowers Price Target to $23
Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $67 to $23.
03-05 03:01
Passage Bio GAAP EPS of -$4.09
Passage Bio press release (PASG): Q4 GAAP EPS of -$4.09. Cash and cash equivalents were $46.3 million as of December 31, 2025, as compared to cash, cash equivalents, and marketable securities of $76.8...
03-04 04:03
Passage Bio Q4 EPS $(4.09) Misses $(2.68) Estimate
Passage Bio (NASDAQ:PASG) reported quarterly losses of $(4.09) per share which missed the analyst consensus estimate of $(2.68) by 52.5 percent. This is a 2.25 percent decrease over losses of $(4.00) per share from the
03-03 20:21
Passage Bio's 2025 net loss narrows
Passage Bio's 2025 net loss narrows Overview Genetic medicines firm's net loss for 2025 was $45.5 mln, smaller than $64.8 mln loss in 2024 Company advancing upliFT-D study for frontotemporal dementia Cash runway expected through Q1 2027 Outlook Passage Bio expects interim safety data from upliFT-D s
03-03 20:10
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
Passage Bio reported 2025 financial results and business highlights, including enrollment of three FTD-GRN patients in Cohort 3 and treatment of the first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of the ongoing upliFT-D study. The company expects to report interim data and seek regulatory feedback in 1H 2026. Huntington’s disease preclinical work is progressing, with clinical candidate selection anticipated in 2H 2026. Cash runway is ex...
03-03 12:00
Passage Bio to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Passage Bio to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference Passage Bio Inc. will participate in the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on Feb. 26, 2026 (8:40 a.m. ET) and the TD Cowen 46th Annual Health Care Conference in Boston on March 4,
02-19 20:00
